Amgen’s Aranesp Faces More Labeling Changes As A Result Of Safety Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory panel meeting also slated for Q1 2008 as part of pharmacovigilance review of ESAs.
You may also be interested in...
ESAs Increase Risk Of Death Among Cancer Patients, JAMA Article Suggests
Data from recent Phase III studies provide mortality signal previously unseen in analyses of the anemia therapies.
ESAs Increase Risk Of Death Among Cancer Patients, JAMA Article Suggests
Data from recent Phase III studies provide mortality signal previously unseen in analyses of the anemia therapies.
Amgen’s March Madness: ESAs, Nplate To Get FDA Advisory Panel Review
Schering’s PegIntron in melanoma will also be reviewed at March 12-13 meeting of FDA’s Oncologic Drugs Advisory Committee.